Reply to "the efficacy and safety of dapagliflozin in pediatric heart failure: Interpreting causality in clinical outcomes". Kumar SS, Gopalakrishnan A, Krishnamoorthy KM, Sivadasanpillai H, et al. Int J Cardiol 2025 Jun 17:133525. doi: 10.1016/j.ijcard.2025.133525.

Read + Share

Amedeo Smart

Independent Medical Education

Kumar SS, Gopalakrishnan A, Krishnamoorthy KM, Sivadasanpillai H, et al. Reply to "the efficacy and safety of dapagliflozin in pediatric heart failure: Interpreting causality in clinical outcomes". Int J Cardiol 2025 Jun 17:133525. doi: 10.1016/j.ijcard.2025.133525.
PMID: 40553801